



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/993,168	11/06/2001	Merrit N. Jacobs	CDS-256	8482

27777 7590 04/25/2005  
PHILIP S. JOHNSON  
JOHNSON & JOHNSON  
ONE JOHNSON & JOHNSON PLAZA  
NEW BRUNSWICK, NJ 08933-7003

EXAMINER

DAVIS, DEBORAH A

ART UNIT	PAPER NUMBER
----------	--------------

1641

DATE MAILED: 04/25/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

**Application No.**

09/993,168

**Applicant(s)**

JACOBS ET AL.

**Examiner**

Deborah A. Davis

**Art Unit**

1641

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

### Status

- 1) ☒ Responsive to communication(s) filed on 31 January 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

### Disposition of Claims

- 4) ☒ Claim(s) 21-29 is/are pending in the application.
- 4a) Of the above claim(s) 26-29 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 21-25 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
  - ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

### Attachment(s)

- |   |   |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)  | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____  |

## **DETAILED ACTION**

### ***Election/Restrictions***

1. Applicant's election without traverse of Group VIII, claims 21-25 in the reply filed on January 31, 2005 is acknowledged. Currently, claims 1-20 are cancelled and claims 26-29 are withdrawn from further consideration.

### **NOTE:**

2. Applicant notes in the election restriction response that a preliminary amendment was filed November 6, 2001 cancelling claims 1-20, leaving only claims 21-29 to be restricted. A new restriction will not be issued since applicant elected claims 21-25.

### ***Claim Rejections - 35 USC § 112***

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claims 21-25 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

5. Claim 21 recites the limitation "the liquid" in step (c) . There is insufficient antecedent basis for this limitation in the claim.

6. Claim 21 recites the limitation "said 10% portion" in step (c ) and (d). There is insufficient antecedent basis for this limitation in the claim.

7. Claim 23 is vague because it is unclear as to what the total possible absorbance at a preselected percent of volume scanned entails. Do all samples have the same

Art Unit: 1641

volume or is applicant using different volumes to indicate agglutination. It is also unclear as to how absorbance, volume and strength of the agglutination reaction relate to the amount of agglutination formed in the sample.

***Claim Rejections - 35 USC § 103***

9. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claim 21 is rejected under 35 U.S.C. 103(a) as being unpatentable over Cusack et al (USP#5,302,348).

The claims are broadly drawn to a method of determining the strength of an agglutination reaction within a hollow container comprising walls capable of transmitting light at certain predetermined wavelengths. The reference of Cusack et al teaches an apparatus and method for performing a coagulation (agglutination) time test on a sample of blood (column 4, lines 23-28). Step (a) of the claim 21 provides a mixture of a sample and an agglutinating reagent within a first cavity of the container, said cavity having a first inside diameter. The reference anticipates step (a) in that it teaches providing a blood sample that flows from a reservoir into a conduit (Figure 2, #30) which examiner interprets as the first cavity. Step (b) comprises transferring the mixture to a second cavity having a second inside diameter substantially smaller than said first inside diameter. The reference teaches that the blood sample flows through the conduit, which is the first cavity, and then to the narrow region (Figure 2, #44) which

Art Unit: 1641

examiner interprets as the second cavity having a second inside diameter substantially smaller than the first inside diameter. The conduit can comprise a clot specific surface that may be plasma treated or otherwise treated to provide more efficient clotting (column 6, lines 32-40), which examiner interprets as an agglutination reagent. Step (c) provides scanning the liquid within the second cavity during step (b) with a beam of light at predetermined wavelengths. The reference of Cusak anticipates step (c) because it teaches that the blood sample present on either side of the conduit or the narrow, which is the second cavity region, can be detected by photoelectric sensors (column 8, lines 59-65), which examiner interprets scanning the sample with a beam of light at predetermined wavelengths. The light emissions from the light sources to the photoelectric sensors pass through the apparatus to the conduit, which contains the blood sample (column 8, lines 20-31), and therefore the sensors would detect light absorbed from the sample. Step (e) requires transferring the mixture back into said first cavity and step (f) requires steps (b) through (d) be repeated until some agglutinated material has separated from non-agglutinated material. The reference of Cusack et al anticipates steps (e) through (f) in describing a pneumatic pump that cycles the blood sample with the test conduit to reciprocally move from one side of the conduit to the other side of the restricted region and then back again. As the blood sample is cycled back and forth, the photoelectric sensors are used to count the time it takes for the blood to traverse the narrowed region and coagulate and clot (column 4, lines 58-68 and column 5, lines 1-2). Step (g) requires calculating the amount of agglutination from the absorbance or scattering detected said step (d). The reference teaches when the

Art Unit: 1641

traversed time of one cycle of travel is a predetermined a percentage longer than an immediately preceding cycle of travel, coagulation is considered to have occurred and the overall time for coagulation is displayed to the operator (column 5, lines 3-9). The examiner interprets this teaching as calculating the amount of agglutination from the absorbance in step (d) as required by step (g). The reference of Cusack et al teaches that as blood traverses back and forth through the narrowing region of the conduit and begins to coagulate and clot, it will occlude the normal flow of the blood sample through the narrowing region of the conduit. The examiner interprets this teaching as the separation of coagulated blood from non-coagulated blood.

The reference of Cusack et al does not teach scanning a 10% portion of the liquid closest to the first cavity of the invention.

However, it would have been obvious to one of ordinary skill in the art to scan the portion of liquid for evaluation that gives the needed information sought after.

Especially since it has long been held to be no more than routine experimentation for one of ordinary skill in the art to discover an optimum value of a result effective variable.

“Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum of workable ranges by routine experimentation.” Application of *Aller*, 220 F.2d 454, 456, 105 USPQ 233, 235-236 (C.C.P.A. 1955). “No invention is involved in discovering optimum ranges of a process by routine experimentation.” *Id.* At 458, 105 USPQ at 236-237. The “discover of an optimum value of a result effective variable in a known process is ordinarily within the skill of the art.” Application of *Voesch*, 617 F.2d 272, 276, 205 USPQ 215, 218-219 (C.C.P.A. 1980).

10. Claims 22-23 is rejected under 35 U.S.C. 103(a) as being unpatentable over Zabetakis et al (USP#5773305) in view of Cusack et al (USP#5302348).

Claim 22 is further drawn to a transfer step wherein the liquid moves tdown from the first cavity to the second cavity so that gravity will assist in the separation of step f). The reference of Zabetakis et al teaches method of diluting a fluid sample for analysis comprising a probe that has a first section with a first diameter and ~~a~~ a second section having a diameter. The fluid sample and diluent are mixed in the second interior section of the probe by moving the sample and diluent back and forth in the second interior section a predetermined number of times by alternate vacuum and pressure forces (gravity) applied to the fluid sample and diluent, (abstract and column 2, lines 1-29).

The reference of Zabetakis et al does not teach the scanning of the sample at predetermined wavelengths or an agglutinating reagent within the first cavity of the apparatus.

However, the reference of Cusack et al teaches a conduit that has been plasma treated to provide more efficient clotting (column 6, lines 32-40) which examiner interprets as an agglutination reagent. The reference of Cusack teaches an optical step wherein the blood sample present on either side of the conduit can be detected by photoelectric sensors (column 8, lines 59-65), which examiner interprets scanning the sample with a beam of light at predetermined wavelengths. The light emissions from



Art Unit: 1641

the light sources to the photoelectric sensors pass through the apparatus to the conduit, which contains the blood sample (column 8, lines 20-31), and therefore the sensors would detect light absorbed from the sample. As the blood sample is cycled back and forth, the photoelectric sensors are used to count the time it takes for the blood to coagulate and clot (column 4, lines 58-68 and column 5, lines 1-2). The reference teaches when the traversed time of one cycle of travel is a predetermined a percentage longer than an immediately preceding cycle of travel, coagulation is considered to have occurred and the overall time for coagulation is displayed to the operator (column 5, lines 3-9). The examiner interprets this teaching as calculating the amount of agglutination from the absorbance in step (d) as required by step (g).

It would have been obvious to one of ordinary skill in the art to want to modify the reference of Zabetakis et al to include detecting agglutination of blood because because the reference of Cusack et al teaches that determining the coagulation time of blood which is necessary in order to stop both internal and external bleeding during surgical procedures (column 1, lines 1-26). One of ordinary skill in the art would want to be motivated to test agglutination of blood also to determine if there is any pre-existing disease that the patient may have that prohibits clotting before performing a surgical procedure. With respect to the second diameter being smaller than the first diameter, it is the position of the examiner that such a modification is an obvious matter of design choice and is generally recognized as being with the level of one skilled in the art.



Art Unit: 1641

11. Claims 24-25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Cusack et al in view of Shepherd et al (WO 94/08237).

The teachings of Cusack et al are set forth above but is silent with respect to the use of radiation at a certain 540 wavelength and detecting the amount of scattered radiation to avoid any hemolysis interference.

However, Shepherd et al teaches a method and apparatus for direct spectrophotometric measurements, which allow accurate determinations of concentrations of various hemoglobin species in whole blood without hemolysis or dilution. This apparatus designed to maximize the true optical absorbance of whole blood and to minimize the effects of light scattering on spectrophotometric measurements of concentrations of various constituent components and to correct the hemoglobin concentration measurements for light scattering and get true optical absorbance. Shepherd et al measured the hemoglobin in blood by selecting a quadruple wavelength in the range of 510-630nm, which minimized the error criterion in absorbance.

It would have been obvious to one of ordinary skill in the art to modify the teaching of Cusack et al to include detecting the amount of scattered radiation to avoid any hemolysis interference as taught by Shepherd et al to get true absorbance values for hemoglobin and other components in the blood for detection. Especially since hemolysis of blood cells causes turbidity, which results in errors in hemoglobin measurements (page 5, lines 1-12). One would be motivated to detect scattered radiation to minimize errors in detection of blood.

***Conclusion***

12. No claims are allowed.

13. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure:


- A. Roger Hage (USP5,898,487) teaches an apparatus and method for determining the concentration of hemoglobin derivatives.
- B. Gavin et al (USP\$,504,011) teaches a portable device for performing coagulation test on a patients' blood.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Deborah A. Davis whose telephone number is (571) 272-0818. The examiner can normally be reached on 8-5 Monday thru Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on (571) 272-0823. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1641

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Deborah A. Davis  
Remsen Bldg.  
Room 3D58  
April 14, 2005



LONG V. LE  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600

64/18/05